Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Bharat Immunological & Biological Corporation Ltd Fundamentals

Market Cap
₹ 135.33 Cr
P/E Ratio (TTM)
0.00
P/B Ratio
0.00
Debt to Equity
0.00
ROE
0.00
EPS (TTM)
0.00
Dividend Yield
0.00 %
Book Value
-7.54

Click here to know more about Fundamentals

Bharat Immunological & Biological Corporation Ltd Financials

Bharat Immunological & Biological Corporation Ltd Financials

Bharat Immunological & Biological Corporation Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 59.25 % 59.25 % 59.25 % 59.25 %
Retail 39.47 % 39.36 % 39.30 % 39.13 %
Others 1.28 % 1.39 % 1.45 % 1.62 %
Mutual Funds 0.00 % 0.00 % 0.00 % 0.00 %
FII 0.00 % 0.00 % 0.00 % 0.00 %

Promoters

59.25%

Retail

39.47%

Others

1.28%

Mutual Funds

0.00%

FII

0.00%

Promoters

59.25%

Retail

39.36%

Others

1.39%

Mutual Funds

0.00%

FII

0.00%

Promoters

59.25%

Retail

39.30%

Others

1.45%

Mutual Funds

0.00%

FII

0.00%

Promoters

59.25%

Retail

39.13%

Others

1.62%

Mutual Funds

0.00%

FII

0.00%

Resistance and Support

₹31.55

PIVOT

resistance-arrow
Resistance
First Resistance₹32.593
Second Resistance₹33.847
Third Resistance₹34.893
support-arrow
Support
First Support₹30.293
Second Support₹29.247
Third Support₹27.993

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day104,94259,69456.88
Week167,73351,2460.00
1 Month167,73352,3690.00
6 Months23,735,96915,922,84471.91

About Bharat Immunological & Biological Corporation Ltd

The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology. BIBCOL was incorporated in 1989. The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets. The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh. BIBCL installed a plant of 100 mln units. Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme. It has set up an R&D unit for the development of hepatitis B vaccine through transfer of technology from the US. In year 2006, the facility was up graded to meet the WHO cGMP & revised schedule M of Drugs & Cosmetics Act. In 2016, BIBCOL switched over to bOPV from tOPV . To add in product line, company diversified into Plasma derived medicines, and Oral Cholera Vaccine.

Managing Director

1989

Founded

Sanjay Kumar Mishra

NSE Symbol

NA

Bharat Immunological & Biological Corporation Ltd Management

NameDesignation
Satish Gupta Chairman
Y K GuptaChairman & Independent Directo
Sreeshan Raghavan Managing Director
Sandip K LalCompany Sec. & Compli. Officer
Alka SharmaIndependent Director
B L Jailkhani Director
Mohd AslamIndependent Director
Sandip Kumar Lal Company Secretary
Sudhanshu VratiIndependent Director
Madhu DikshitIndependent Director
Sanjay Kumar MishraManaging Director
Pankaj KumarIndependent Director

Bharat Immunological & Biological Corporation Ltd News

Bharat Immunological & Biolog.Corp. announces board meeting date
On 8 March 2024
Bharat Immunological & Biolog.Corp. to convene AGM
On 29 December 2023
Bharat Immunological & Biolog.Corp. to conduct AGM
On 29 December 2023
Bharat Immunological & Biological Corporation reports standalone net loss of Rs 4.92 crore in the September 2023 quarter
Reported sales nil
Bharat Immunological & Biolog.Corp. to conduct board meeting
On 31 October 2023
Bharat Immunological & Biolog.Corp. to convene board meeting
On 24 April 2023
Bharat Immunological & Biological Corporation reports standalone net loss of Rs 4.68 crore in the December 2022 quarter
Reported sales nil
Bharat Immunological & Biolog.Corp. to announce Quarterly Result
On 9 February 2023
Bharat Immunological & Biological Corporation Ltd leads losers in 'B' group
Bonlon Industries Ltd, Gujarat Lease Financing Ltd, Umiya Tubes Ltd and Hybrid Financial Services Ltd are among the other losers in the BSE's 'B' group today, 28 December 2022.
Bharat Immunological & Biological Corporation Ltd leads losers in 'B' group
Earum Pharmaceuticals Ltd, Coastal Corporation Ltd Partly Paidup, Syncom Formulations (India) Ltd and STL Global Ltd are among the other losers in the BSE's 'B' group today, 27 December 2022.

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
Sun Pharmaceuticals Industries Ltd₹ 358724.57 Cr
₹ 1,495.10
(-2.87 %)
87.07
Cipla Ltd₹ 120233.22 Cr
₹ 1,489.15
(0.46 %)
32.36
Zydus Lifesciences Ltd₹ 109282.04 Cr
₹ 1,086.05
(0.50 %)
31.67
Divis Laboratories Ltd₹ 109187.23 Cr
₹ 4,113.00
(1.34 %)
80.00
Dr Reddys Laboratories Ltd₹ 98384.41 Cr
₹ 5,897.70
(0.42 %)
22.64

Bharat Immunological & Biological Corporation Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Bharat Immunological & Biological Corporation Ltd shares in BlinkX

Bharat Immunological & Biological Corporation Ltd's P/E ratio is 0.00 times as of May 23, 2024 at 04:00 PM.

Bharat Immunological & Biological Corporation Ltd's most recent financial reports indicate a price-to-book ratio of 0.00, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Bharat Immunological & Biological Corporation Ltd's market is 135 Cr as on May 23, 2024 at 04:00 PM.

The current financial records of Bharat Immunological & Biological Corporation Ltd show a 0.00% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

According to Bharat Immunological & Biological Corporation Ltd's most recent financial filings, the company has a total asset value of Crores, which includes current and non-current assets such as inventory, cash, properties, and equipment.

As of the Mar 2024 quarter, the promoter shareholding in Bharat Immunological & Biological Corporation Ltd stands at 59.25%. During the same period, Institutional Investors have shown a slight values are equal in their holdings, values are equal from 0.00% to 0.00%.